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Background: In vitromodels of prostate cancer (PCa) are not always reliable to evaluate
anticancer treatment efficacy. This limitation may be overcome by using viable tumor
slice material. Here we report on the establishment of an optimized ex vivo method to
culture tissue slices from patient-derived xenografts (PDX) of prostate cancer (PCa), to
assess responses to PCa treatments.
Methods: Three PDX models were used that are characterized by different androgen
receptor (AR) expression and different homology directedDNA repair capacities, due to a
breast cancer associated two (BRCA2)wild-typeormutated status. Tumorswere removed
from mice, sliced using a vibratome and cultured for a maximum of 6 days. To test the
sensitivity to androgen antagonist, tumor slices from the AR-expressing and AR-negative
PDX tumors were treated with the anti-androgen enzalutamide. For sensitivity to DNA
repair intervention, tumors slices from BRCA2wild-type andmutated PDXswere treated
with the poly (ADP-ribose) polymerase-1 inhibitor olaparib. Treatment response in these
tumor slices was determined bymeasuring slicemorphology, cell proliferation, apoptosis,
AR expression level, and secretion of prostate specific antigen (PSA).
Results: We compared various culture conditions (support materials, growth media,
and use of a 3D smooth rocking platform) to define the optimal condition to maintain
tissue viability and proliferative capacity up to least 6 days. Under optimized
conditions, enzalutamide treatment significantly decreased proliferation, increased
apoptosis, and reduced AR-expression and PSA secretion of AR-expressing tumor
slices compared to AR-negative slices, that did not respond to the intervention.
Olaparib treatment significantly increased cell death inBRCA2mutated tumors slices as
compared to slices from BRCA2 wild type tumors.
Conclusions:Exvivo treatmentofPCaPDXtumor sliceswithenzalutamide andolaparib
recapitulates responses previously observed in vivo. The faithful retention of tissue
structure and function in this ex vivo model offers an ideal opportunity for treatment
efficacy screening, thereby reducing costs and numbers of experimental animals.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial purposes.
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1 | INTRODUCTION
Prostate cancer (PCa) is the second most common cancer in men
and the fourth most common tumor type worldwide.1 PCa
remains a high burden in the current healthcare system, especially
once it develops into castration resistant PCa (CRPC). Although
therapeutic strategies have improved over the past decades, their
gains are often transient and only marginally increase survival of
CRPC patients. Therefore, there is a clear unmet clinical need for
better treatment options and predictive markers for CPRC
patients. Currently, a multitude of novel targets and compounds
are in the pipeline for testing. In order to speed up the process
from development toward clinical use, faster and better test
models are urgently needed. When developing and testing novel
therapies, it is essential to have a cancer model that is both
reliable and representative.
Most preclinical studies of PCa depend heavily on immortalized
cancer cell lines, which are grown in culture dishes as a two-dimensional
model. These models do not recapitulate the complex architecture of
tumors nor the important interaction between tumor cells and their
microenvironment.2 They do therefore not always accurately predict
treatment efficacy and these limitations could lead to a failure when
transitioning a new drug from the bench to the clinic.
As an alternative, ex vivo culturing of tumor slices represent a
solid model system for drug sensitivity testing due to its relatively
short generation time and reflection of the tumor microenviron-
ment.3–7 For example, several studies have shown that
breast tumor tissue slices can be used to assess chemotherapy
response in the context of personalized medicine.8–10 In
recent years, efforts have been undertaken to establish such
strategies to generate primary cultures from human
prostate tumors and innovative complex culture systems.
Unfortunately, the establishment of primary PCa organotypic
cultures proved to be extremely challenging due to the slow-
growing characteristics of the PCa cells; basal epithelial cells
proliferate faster than tumor cells and often outgrow them during
prolonged culture.11–13
To allow testing of therapy responses in different genetic and
functional backgrounds of PCa, we set out to develop an optimized
tissue slice culture system. We used well-established patient-derived
xenograft (PDXs)models as a source for the tissue slices14–16 and show
that our tissue slice culture system provides treatment outcome that
recapitulates responses previously found in vivo.
2 | MATERIALS AND METHODS
2.1 | Reagents
Reagents were purchased from Sigma-Aldrich (Darmstadt, Germany)
unless otherwise specified.
2.2 | Collection of PDX tumor tissue
PDXsofPCa(PC295,PC339,andPC310)wereestablishedbyvanWeerden
et al14 and were routinely passaged by subcutaneous grafting of small
fragments onto both shoulders of intact male athymic NMRI nu/nu mice
(Taconic Biosciences, Cologne, Germany). Characteristics of the different
PDXs are summarized in Table 1. Fresh PDX tumors with volume of
500–1000mm3were obtained. After removal frommice, the tumors were
kept on ice in Dulbecco'sModified EagleMedium (DMEM; Lonza, Verviers
Sprl, Belgium).
2.3 | Tissue slice and culture
Tumor slices were generated using a vibratome (Leica VT1200S; Leica,
Nussloch, Germany) with a thickness set at 300 µm, vibration
amplitude at 3.0mm and slicing speed at 0.6 mm/sec. Slices were
either submerged directly in 3mL culture medium or placed on Falcon
40 µm Cell Strainers or Millicell 0.4 µm Cell inserts (Merck Millipore,
Bedford, UK) and then cultured in 3mL culture medium in six well
plates. The culture media that were tested for quality assessment are
summarized in Table 2. Slices were put in culture within 3 h after the
tumor was removed from the mouse. Culturing was performed at 5%
CO2 at 37°C and at atmospheric oxygen levels. Culture plates were
TABLE 1 Overview of characteristics of different PDXs14–16
PDX Origin1 AD2 AR3 PSA4 BRCA TD (days)5 Pathology type
PC295 LN + + + WT5 9-11 adenocarcinoma
PC339 TURP - - - WT 4-7 adenocarcinoma
PC310 PC + + + HD6 9-11 adenocarcinoma
1LN, lymph nodemetastasis; TURP, transurethral resection of the prostate; PC, primary prostate tumor; 2AD, androgen dependence; 3AR, androgen receptor;
4PSA, prostate specific antigen; 5WT, wild type; 6HD, homozygous deletion; 5TD, Tumor doubling time
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standing still or were subjected to movement at 6 rpm using Luckham
4RT Rocking Table (Luckham 200 Ltd, West Sussex, UK). One third of
medium was refreshed and collected daily. Slices were harvested at
various time points and fixed in 10% neutral buffered formalin for at
least 24 h at room temperature (RT). Subsequently, tumor slices were
embedded in paraffin and 4 µm sections were made for further
microscopy analysis (for practical setup, see Figure 1).
2.4 | Ex vivo antiandrogen and PARP-1 inhibitor
treatment
To test the response of antiandrogen and poly (ADP-ribose)
polymerase-1 (PARP-1) inhibitor treatment, tissue slices were cultured
under optimal conditions and treated with enzalutamide (1 µM,
Sequoia Research Products, Pangbourne, UK), olaparib (10 µM, Selleck
Chemicals, Munich, Germany), or with vehicle control (dimethyl
sulfoxide, DMSO) for different time points.
2.5 | Hematoxylin and eosin staining
Histological tumor architecture was examined by hematoxylin and
eosin (H&E) staining. Briefly, sections were deparaffinized in xylene
followed by rehydration in graded alcohols. They were then stained
with hematoxylin for 1min, rinsed with tap water, stained with eosin
for 1 min, and rinsed again with tap water. The slides were then
dehydrated with increasing concentration of ethanol successively
followed by xylene and mounted with entellan.
2.6 | Immunohistochemical and fluorescent
procedures
Sections were deparaffinized in xylene followed by rehydration in
graded alcohols. Antigen retrieval was performed with target
retrieval buffer (Dako, Glostrup, Denmark). For diaminobenzidine
(DAB) staining, endogenous peroxidase activity was blocked by
using 3% hydrogen peroxide solution in methanol at RT for
TABLE 2 Overview of the different medium compositions
PGM aDMEM/F12 K M199: K-SFM DMEM
DMEM/Ham's F12 (1:1)
BSA (0.01%) FCS (2%)
Epidermal growth factor (10 ng/mL)
Insulin-transferrin-selenium (1%)
Hydrocortison (0.5 μg/mL)
Triiodothyronine (1 nM)
Phosphoethanolamine(0.1 mM)
Cholera toxin(50 ng/mL)
Fibronectin(100 ng/mL)
Fetuine (20 μg/mL)
R1881(0.1 nM)
Penicillin/streptomycin
(100 U/mL, 100 μg/mL)
PFMR-4A
(aDMEM/F12 K)
M199: K-SFM (1:1)
Antibiotic/antimycotic solution
DMEM-high glucose
Penicillin/streptomycin
(100 U/mL, 100 μg/mL)
FIGURE 1 PDX tissue culture methodology. The tumor was removed from the mice and sliced with a Leica Vibratome into 300 µm tumor
slices. Slices were either submerged in culture medium, on Cell Strainers or on Cell Culture inserts. Culture dishes were then placed on a
Rocking Table or incubated without movement. Slices were harvested at various time points and EdU was added 2 h before fixation.
Subsequently, fixed tissue was embedded in paraffin (FFPE)
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20 min. 5% bovine serum albumin (BSA) in phosphate buffered
saline (PBS, Lonza, Verviers, Belgium) was used to block
nonspecific binding. Primary androgen receptor (AR) antibody
(M4074, 1/200, SPRING Bioscience, Pleasanton, CA) and Ki67
antibody (ab16667, 1/200, Abcam, Cambridge, UK) diluted in
blocking buffer were applied to the sections at 4°C overnight.
Ki67 was detected with anti-rabbit Alexa Fluor 488 and mounted
with Vectashield containing DAPI (Vector Laboratories, Burlin-
game, CA). AR staining continues with a horseradish peroxidase
(HRP)-conjugated anti-rabbit IgG secondary antibody (Dako) at a
1:100 dilution for 1 h at RT. AR positive cells were visualized
using DAB staining kit (Agilent, Santa Clara, CA) followed by
counterstaining with hematoxylin. Negative controls were per-
formed for all samples by omitting the primary antibodies.
2.7 | EdU incorporation and Click-iT™ reaction
5-ethynyl-2′-deoxyuridine (EdU, Invitrogen, Carlsbad, CA) at a
concentration of 3 µg/mL was added to the culture medium 2 h
before fixation. For the Click reaction, tissue sections were deparaffi-
nized in xylene followed by rehydration in graded alcohols and then
blocked with PBS containing 1% BSA. After additional washing with
PBS, sections were incubated with freshly made Click-iT Alexa Fluor
594 cocktail buffer for 30min as previously reported.10 Samples were
mounted using Vectashield mounting medium with DAPI.
2.8 | TUNEL assay
Terminal deoxynucleotidyl transferase dUTP nick end-labeling (TU-
NEL) assay was performed using In Situ Cell Death Detection Kit
(Roche Life Sciences, Penzberg, Germany) according to instruction of
the manufacturer.
2.9 | Medium prostate-specific antigen (PSA)
measurement
Tumor slices culture medium (1mL) was collected daily for PSA
measurement. The PSA concentration was measured using a PSA
enzyme-linked immunosorbent assay (ELISA) kit (Abnova, Taipei City,
Taiwan) according to the manufacturer instructions. The accumulated
PSA concentration in the culture medium was calculated using the
following formula (which corrects for medium removal each day):
PSAtotal dð Þ ¼ PSAmeasured dð Þ*3þ 1=3 PSAtotal d 1ð Þ
In which d ¼ day of culture:
2.10 | Image acquisition
AR staining was imaged using a light microscope (Olympus, Tokyo,
Japan) and four fields (200× magnification) from each section were
captured. For Ki67, EdU, and TUNEL staining quantifications, 10
random images (400× magnification) from each tumor slice section
were generated using a Leica fluorescence microscope (DM4000b) to
represent the slice heterogeneity. Representative EdU and TUNEL
photos were taken by using a Leica SP5 confocal microscope (Leica,
Nussloch, Germany). Image size:512 × 512 pixels, pixel size 0.7 µm,
200× magnification.
2.11 | Image quantification
AR expression was quantified by Image J software to yield the pixel
ratio of AR positive to total nuclei. To quantify the TUNEL microscopy
images, all pictures were analyzed with the Fraction of overlap with
Otsu's thresholding method: The DAPI and the TUNEL image were
both thresholded according to Otsu's algorithm17 which resulted into
two binary images. The pixel number was measured and subsequently
the Mander's M1 coefficient was used to calculate the fraction of
TUNEL positive pixel overlapped with DAPI pixel.18 To quantify the
fraction of EdU positive cells, the fraction of overlap of silhouette
images method was used. This method relies on edge detection to
obtain a binary image. For both the DAPI and EdU pictures, a gradient
magnitude image was obtained from the image of entry. This binary
image was created using a modified triangle-thresholding method in
which black areas completely enclosed by white areas were filled.19
Next, a morphological dilation was applied using a circular structuring
element with a radius of three pixels. All pixels that still had a value of
one then constitute a newly formed gradient mask image. The same
thresholding was applied to the original grayscale image. The
intersection of this image and all pixels greater than themean intensity
of the original grayscale image formed the intensitymask image. A new
image was obtained through seeded region growing, whereby the
gradient mask served as a seed point image and the intensity mask as
the target image. This newly formed image was subjected to a median
filter with a 5 × 5 neighborhood and all pixels equal to one constitute
the final binary image. Finally, Mander's M1 coefficient was calculated
for the fraction of overlap.
2.12 | Statistical analysis
Results are expressed as the mean ± SEM or median ± quartile in bar
graph. Mann-Whitney test was used to analyze the differences
between two groups. Statistical analysis and generation of graphs was
performed using Graphpad Prism 6.0 (La Jolla, CA). P < 0.05 was
considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001.
3 | RESULTS
3.1 | Culture condition selection
To establish the most optimal culture method for preservation of PCa
tissue slice viability we developed an optimized culture system and
compared it to previously reported systems.20,21 Tumor slices from
PC295, PC339, and PC310 PCa PDXs were generated using a
vibratome and these slices were cultured in prostate growth medium
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FIGURE 2 Effect of filter support and 3D orbital movement on PCa tissue slice morphology and viability. A, Representative H&E
images of PC295 tumor slice sections after 4 days of culturing under the different culture conditions, compared to an initial slice (day
0). Scale bar 50 µm. B, Representative EdU/TUNEL/DAPI images of PC295 tumor slice sections after 4 days of culturing under the
different culture conditions, compared to an initial slice (day 0) (blue = DAPI, red = EdU, green = TUNEL). Represented H&E and EdU/
TUNEL images of PC339 and PC310 tumor slices can be found in Figure S1. Scale bar 50 µm. C, Quantification of the fraction of EdU-
positive cells in the tissue slices. D, Quantification of the fraction of TUNEL positive cells in the tissue slices. For all graphs, 10 image
fields were analyzed per tumor slice. Each point represents one image field, interquartile range, and median values are indicated
(results from 1 representative tumor per graph)
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(PGM) for 4 days under the different conditions in which we compared
supporting materials (Figure 1). Furthermore, stationary condition and
3D orbital movement on a rocking table were compared as smooth 3D
orbital movement could increase oxygen and nutrition exchange as
reported previously.21 H&E stained sections of slices of all three
tumors showed that slices cultured on cell strainers maintained tissue
morphology, while slices cultured without support or on inserts lost
tissue integrity and showed an increase in apoptotic nuclei and
vacuolated structures over time (Figure 2A and Figure S1). Moreover,
in contrast what was observed previously using inserts, we did not
observe a viability gradient nor loco-regional changes inmorphology.15
The thymidine analog EdU was used as a real-time proliferation
marker to assess tissue viability. We tested the reliability of our newly
developed EdU quantification algorithm by comparing automatic
counting with manual counting and a good correlation was observed
(an R2 of 0.922 and 0.841, respectively for two individuals compared to
automatic counting; Figure S2). A large variability of EdU-positive cells
was observed between individual image fields, and therefore, 10 fields
of view were quantified per slice to provide a reliable assessment.
Tissue slices cultured on cell strainers and under continues 3D orbital
movement outperformed the other tissue slice methods when looking
at maintenance of proliferation at day 4 (Figures 2B and 2C). We
further evaluated the induction of cell death during ex vivo culturing by
TUNEL staining, which labels DNA strand breaks generated during
apoptosis.22 In line with the results on proliferation, slices cultured on
cell strainers did not show an increase in apoptosis at 4 days of culture,
while slices cultured under the other conditions showed enhanced
apoptosis. No significant difference in TUNEL signal was observed
between slices in the stationary condition and those cultured on a
rocking table (Figures 2B and 2D). From the EdU and TUNEL results
combined, we concluded that cell strainer-support and continuous 3D
orbital movement are optimal for maintenance of tissue slice
morphology, proliferation, and viability.
3.2 | Optimal medium selection
The culture medium composition has vital impact on the viability of
tissue slices. To select the optimal medium, we therefore tested four
different culture media that have been reported previously for primary
prostate cell or tumor culturing (Table 2).20,21,23–25 Tissue morphology
analysis showed that Prostate GrowthMedium (PGM)24 and aDMEM/
F12 K outperformed the other media tested (Figure S3).We compared
incubation of tissue slices from PC295 and PC339 to determine which
medium preserved tumor cell viability most optimally. Average tissue
proliferation remained constant for PC339 (average 10%) up to 6 days
of culturing in both media while proliferation of PC295 reduced over
time in both media (initial 10.7%, and 2.5% and 3.6% in PGM and
aDMEM/F12 K, respectively after 6 days). There was no significant
difference in performance between the two culture media for both
PDXs (Figure 3A).
PGM constitutes 2% fetal calf serum (FCS) and is supplemented
with the synthetic androgen R1881 (0.1 nM), while aDMEM/F12 K
devoid of FCS and does not contain R1881. The clear benefit of using
serum-free medium led us to test the impact of addition of the same
concentration of R1881 to the aDMEM/F12 K medium. Three tumors
of PC295 and PC339 each were cultured under optimal conditions in
aDMEM/F12 K or in aDMEM/F12 K supplemented with R1881. We
found a significantly higher proliferation rate of the PC295 slices
cultured in aDMEM/F12 K supplemented with R1881 compared to
aDMEM/F12 K without R1881 (1.9 fold at day 6) (Figure 3B). As
expected, addition of R1881 did not affect proliferation rates of
androgen independent PC339 slices (Figure 3B). Some increase in
apoptosis was observed in PC339, while PC295 maintained its low
apoptosis levels for up to 6 days of ex vivo culturing (Figure 3C).
To further assess tissue maintenance, we measured AR expres-
sion, a major characteristic of androgen dependent prostate tumors.
Immunohistochemical stainings showed that AR expression was
largely maintained during ex vivo culturing of PC295 slices, with a
small but significant decrease of AR expression in slices cultured at
6 days in either PGM or aDMEM/F12 K (Figures 4A and 4B). The
addition of R1881 to aDMEM/F12 K medium preserved AR levels up
to 6 days of incubation (Figures 4C and 4D).
Because androgen stimulates PSA secretion from PCa cells, we
measured PSA levels in the culture media. Medium from PC295 tumor
slices was collected for up to 6 days and PSA accumulation was
monitored. After normalization to initial PSA levels, we observed a
continuous increase in PSA for up to 6 days in cultures supplemented
with R1881 while slices cultured in aDMEM/F12 K without R1881
showed a stabilization of PSA levels (Figure 4E). Altogether, we
concluded that serum-free aDMEM/F12 K plus R1881 is the optimal
medium for further use showing maintenance of tissue slice
morphology, viability, and AR-functionality.
3.3 | Enzalutamide treatment of tissue slices
In order to validate the accuracy of the tissue slice system to reflect
clinical responses to relevant therapies, we investigated the response to
enzalutamide, a second generation antiandrogen which is currently
being tested in a randomized phase III trial.26 PC295 (AR positive and
androgen dependent) and PC339 (AR negative and androgen indepen-
dent) slices were treated with enzalutamide with or without R1881. As
shown inFigure5A,weobserveda significantdrop in the fractionofEdU
positive cells in PC295 slices treated with enzalutamide after 6 days of
culturing (decreased by a factor of 5.5), while we did not observe a
change in proliferation in PC339 slices. Simultaneously, a significant of
2.8 folds increase of TUNEL positive cells was observed in PC295 slices
treated with enzalutamide, with no effect in the PC339 slices
(Figure 5B). Presence of R1881 was unable to restore proliferation or
revert apoptosis induced by enzalutamide treatment in PC295 slices
(Figures 5A and 5B). AR staining of PC295 slices showed a dramatic
reduction of 45% upon enzalutamide treatment at day 6 which could
also not be reversed by the presence of R1881 (Figure 5C). PSA
measurement inmediumsamples further confirmed the inhibitoryeffect
of enzalutamideonARpositive tumor slices.After an initial rise in PSAat
day 2, PSA secretion decreased after enzalutamide treatment, both in
presence or absence of R1881 (Figure 5D). Similar antiandrogenic
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effects of enzalutamide were observed in tumor slices from the AR
positive and androgen dependent PC310 PDX model (Figure S4).
3.4 | Olaparib treatment of tissue slices
Mutations in the DNA repair gene BRCA2 have been identified in PCa
patients, and previous studies have shown that these specific patients
benefit from treatment with olaparib, an inhibitor of poly[adenosine
diphosphate (ADP)-ribose] polymerase-1 (PARP-1).27 We therefore
assessed the response to olaparib treatment in PC295 (BRCA2 wild-
type) and PC310 (BRCA2 mutated) tumors. A significant drop in the
fraction of S-phase cells was observed for both PC295 and PC310
tumor slices (decreased by a factor of 2.65 and 10, respectively) when
treated with olaparib for 6 days, with a more pronounced reduction in
FIGURE 3 Optimization of culture medium. A, Quantification of the fraction of EdU-positive cells of PC295 and PC339 slices cultured up
to 6 days in PGM and aDMEM/F12 K medium. B, Quantification of the fraction of EdU-positive cells for PC295 and PC339 slices cultured up
to 6 days in aDMEM/F12 K and aDMEM/F12 K supplemented with R1881. C, Quantification of the fraction of TUNEL-positive cells for
PC295 and PC339 slices cultured in aDMEM/F12 K and aDMEM/F12 K supplemented with R1881 at 6 days. For all graphs, 10 image fields
were analyzed per tumor slice section. Each point represents one image field, average and SEM are indicated (three independent experiments
for each tumor type). **P < 0.01, ***P < 0.001, ns, non-significant
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cell proliferation for PC310 (Figure 6A). A significant increase of 10.9
folds of TUNEL positive cells was observed only in PC310 slices
treated with olaparib, and not in PC295 tumor slices (Figure 6B). AR
staining showed a reduction of AR positive tumor cells in PC310 tumor
slices upon olaparib treatment, while only a slight reduction of AR-
positive tumor cells was observed in PC295 tumor slices (Figure 6C).
PSA measurement revealed reduced PSA levels of both PC295 and
PC310 slices (Figure 6D). In conclusion, both BRCA2 deficient and
proficient tumors are hampered by olaparib treatment, but only BRCA2
deficiency causes induction of apoptotic cell death.
4 | DISCUSSION
We have established an optimized ex vivo tissue slice culture system
using PCa PDXs. Under optimal culture conditions, tumor morphology,
cell proliferation, and prostatic characteristics are preserved for up to
6 days with minimal induction of cell death. Furthermore, we showed
that this system is suitable for PCa drug testing: we observed responses
to enzalutamide in androgen dependent tumor slices as well as to
olaparib in BRCA2 mutant tumor slices that reflect in vivo therapy
responses.
An ex vivo tumor culture system should maintain cancer
characteristics and tumor proliferating capacity during ex vivo
culturing to allow reliable therapy response evaluation. Since the
1970s, various studies have been described that aim to establish an ex
vivo culture system for PCa tumors. This has resulted in the
development of different tumor culture methods, ranging from direct
culturing of 1-2mm3 human tissue samples in medium to more
recently developed techniques to culture precision cut tissue slices on
various scaffolds and supporting filters, such as gelatin, collagen
sponges, or titanium mesh inserts.21,23,28,29 As reported in these
studies, maintenance of prostate or PCa tissue slices for a week could
FIGURE 4 Prostate characteristics during prolonged ex vivo culturing. A, Representative images of AR staining of PC295 tumor slice
sections cultured in two media for different time points, compared to the stained section of the initial slice (day 0). B, Quantification of the
AR staining. Four image fields were analyzed per tumor slice, each point represents one image field, average, and SEM are indicated (three
independent experiments). C, Representative images of AR staining of PC295 tissue slice sections cultivated in aDMEM/F12 K and aDMEM/
F12 K supplemented with R1881 for different time points, compared to the stained section of the initial slice (day 0). D, Quantification of the
AR staining. Four image fields were analyzed per tumor slice, each point represents one image field, average, and SEM are indicated (three
independent experiments). E, Normalized accumulated PSA concentrations of PC295 slices from day 1 to day 6 cultured in aDMEM/F12 K
and aDMEM/F12 K supplemented with R1881. Line represent mean values and bars indicates SEM (three independent experiments). For all
graphs scale bar 50 µm and *P < 0.05, **P < 0.01, ***P < 0.001, ns, non-significant
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be achieved, but conservation of tissue structure and functionality was
not always comprehensively reported with extensive variability in
tissue origin and evaluation in the different studies. Application of the
ex vivo culture system for drug testing was only reported in a few
studies, describing reduced cell proliferation in response to genis-
tein,29 cisplatin combined with a BcL-2 antagonist,30 heat shock
protein 90 inhibitors28 PARP-1 inhibitors,31 and most recently
published studies with bicalutamide32 and docetaxel.33 However
detailed cell cycle progression (proliferation) of the tumor cells was not
investigated, making direct comparison to our studies difficult.
Importantly, our study validates the response to different tumor
genotypes, represented by different PDXs, and hence provide
evidence that ex vivo drug testing can indeed predict in vivo responses.
Although ex vivo tumor cultures from other cancer types can be
maintained for weeks or months,8,11,12,34–36 PCa tissue maintenance
of primary tumors has been challenging probably due to the slow-
growing characteristics and fast proliferation of basal cells.25,37,38 Also,
obtaining aggressive metastatic PCa material is met with limitations as
metastatic disease is predominantly found in bone restricting easy
excess. Nowadays, prostate-specific membrane antigen (PSMA)
guided biopsy and salvage lymphadenectomy is reported,39–41 which
may offer new opportunities for acquiring aggressive PCa material for
FIGURE 5 Response to ex vivo enzalutamide treatment. A, Quantification of the fraction of EdU-positive cells for PC295 and PC339 slices
at different time points. Scale bar 100 µm. B, Quantification of the fraction of TUNEL-positive cells for PC295 and PC339 slices at different
time points. Scale bar 100 µm. C, Representative images of AR staining for PC295 tissue slice sections at day 6 and quantification of the AR
stainings. Scale bar 50 µm. D, Normalized accumulated PSA concentrations of PC295 and PC339 slices from day 1 to day 6 treated or not
with Enzalutamide. Line represent mean values and bars indicates SEM. Ten image fields for EdU/TUNEL and four image fields for AR were
analyzed per tumor slice section. Each point represents one image field, average, and SEM are indicated (four independent experiments for
each tumor type). *P < 0.05, **P < 0.01, ***P < 0.001, ns, non-significant
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FIGURE 6 Response to ex vivo olaparib treatment. A, Quantification of the fraction of EdU-positive cells of PC295 and PC310 slices
treated with olaparib for 6 days. B, Quantification of the fraction of TUNEL positive cells of PC295 and PC310 slices treated with olaparib for
6 days. C, Representative images of AR staining of PC295 and PC310 slices treated with olaparib for 6 days. Scale bar 50 µm. D, Normalized
accumulated PSA concentrations of PC295 and PC310 slices from day 1 to day 6 treated or not with olaparib. Ten image fields for EdU/
TUNEL and four image fields for AR were analyzed per tumor slice section. Each point represents one image field, average and SEM are
indicated (three independent experiments for each tumor type). *P < 0.05, **P < 0.01, ***P < 0.001, ns, non-significant
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ex vivo drug response tests. Our tissue slice culture platform for PCa
defined in this study may be helpful to standardize ex vivo culturing of
patient material.
We used PDX tumors to thoroughly evaluate the impact of different
culture condition and the ability of tissue slices to recapitulate tumor
responses characteristic for a particular genotype. PDX tumors have
limited intra-tumoral heterogeneity and high tumor content which allows
for intensive technical studies. In order to reduce slice heterogeneity from
the same tumor as much as possible, slices were consecutive allocated to
each experimental treatment. We were able to keep longevity of tumor
slices by using serum-free aDMEM/F12K medium with the addition of
synthetic androgen up to 6 days. This medium shares many similar
ingredients with medium PFMR-4A which was reported previously for
successful maintenance of benign andmalignant prostate tissue slices for
5 days.21 Serum-free medium allows more precise evaluations of cellular
function and better control over physiological responsiveness.
One of the strengths of this study is the use of EdU incorporation
to assess cell proliferation, allowing real time measurement of DNA
synthesis during replication.We believe that this is a more reliable way
to measure early treatment effects compared to the commonly used
Ki67marker. Ki67 protein is present in all cycling cells, even for several
days after cells have ceased to proliferate.42 Indeed, we observed a
disparity between EdU ratio and Ki67 expression: after 6 days
culturing EdU ratio dropped significantly while Ki67 only showed a
slight reduction (Figure S5). In the majority of tumor slices from all
three PDXs tested, we observed an increase of proliferation after one
day of incubation, followed by maintenance of proliferation for PC339
and PC310, or only a slight decrease of proliferation in case of PC295
compared to day 0. The first-day proliferation boost might be a result
of the availability of a high level of nutrients and oxygen. The initial high
TUNEL level in PC339 slices is most likely due to a higher level of
necrosis in the original tumor sample, since TUNEL assay is unable to
distinguish necrosis and apoptosis.43
We observed a marginal effect of androgen deprivation on tumor
slice viability in androgen responsive PDX tissue slices. This might be
caused by the presence of endogenous androgen maintained in the
tumor slices and which is gradually released into the medium during
culturing. Thus,endogenouslypresentandrogencanbeused tomaintain
activation of AR signaling and proliferation for a few days. Similar
observations were done by Zhou et al44 in rat prostates that retained
similar androgen tissue levels independent of the serum concentrations.
A clear antiandrogenic response to enzalutamide was observed in
androgen dependent tissue slices of PC295 and PC310. Our ex vivo
response of tissue slices to enzalutamide are also supported by in vivo
data reported by Guerrero et al45 in which enzalutamide inhibits tumor
growth significantly during the first 6 days of treatment comparedwith
vehicle-treated mice. Additionally, we showed that olaparib induced
cell death in the BRCA2 mutant PC310 tumor slices, confirming the
expected response when targeting DNA damage repair deficient
tumors. This was in concordance with recent clinical studies, showing
that that CRPC patients with somatic loss and germline mutation of
BRCA2 respond well to olaparib.27 Similar was reported by Beshiri
et al46 for PCa PDX organoid cultures in which BRCA2 deficiency
correlates with olaparib sensitivity. PARP-1 inhibitors with high PARP
trapping potency, such as olaparib, can yield intense replication
stress,47,48 which can explain the decrease of fraction of S-phase cells
in the BRCA2 wild-type PC295 slices.
So far, several publications have suggested that tumor tissue slice
culture can be utilized to predict drug response in breast cancer8–10 and
monitor cytotoxic drug effects in liver, intestine, and lung.49–51Wehave
established dedicated tissue slice system for PCa that shows robust and
specific antiandrogen and PARP-1 inhibition treatment effects and that
can be extended to testing of novel compounds relevant to PCa.
5 | CONCLUSIONS
The faithful retention of tissue structure and function in our ex vivo
culture system offers an opportunity to evaluate PCa response to
therapeutic compounds making it an ideal system for low to medium
throughput testing in drug discovery.
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